GTC Clinical Trials

GTC Biotherapeutics has completed Phase III American and European clinical trials with recombinant human antithrombin in patients with hereditary antithrombin deficiency and is no longer recruiting patients for these studies.

Our first HD clinical trial resulted in an approval in Europe in 2006.
Click here to read more detail on this decision by the European Union.

In February 2008, GTC completed enrollment in a US clinical trial
with recombinant human antithrombin in patients with hereditary AT deficiency (HD).
Click here to read more detail describing the progress of this study.

Do you treat HD patients? We encourage you to join our physician registry. Help us understand the demographics and natural history of this coagulation disorder.